A Phase 1, Single-Center, Five-Period, Single and Multiple Dose, Double-Blind, Placebo-Controlled First-in-Man Study to Assess the Safety and Pharmacokinetics of ZYN001 Administered as a Transdermal Patch to Healthy Adults

Trial Profile

A Phase 1, Single-Center, Five-Period, Single and Multiple Dose, Double-Blind, Placebo-Controlled First-in-Man Study to Assess the Safety and Pharmacokinetics of ZYN001 Administered as a Transdermal Patch to Healthy Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs ZYN 001 (Primary)
  • Indications Fibromyalgia; Neuropathic pain
  • Focus Adverse reactions; First in man
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2017 Status changed from planning to recruiting, according to a Zynerba Pharmaceuticals media release.
    • 17 Oct 2016 This trial is expected to begin in the first half of 2017, according to a Zynerba Pharmaceuticals media release.
    • 11 Aug 2016 Zynerba expects to initiate Phase 1 studies in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top